Serological response after SARS-CoV2 vaccination in healthcare workers: a multicenter study

Main Article Content

Giovanni Visci
Carlotta Zunarelli
Ihab Mansour
Stefano Porru
Giuseppe De Palma
Xavier Duval
Maria Grazia Lourdes Monaco
Gianluca Spiteri
Angela Carta
Giuseppe Lippi
Giuseppe Verlato
Emanuele Sansone
Emma Sala
Massimo Lombardo
Mahsa Abedini
Francesco Violante
Paolo Boffetta

Keywords

Health care workers, SARS-CoV-2, Vaccination, Immunologic response, Antibodies

Abstract

Introduction: Characterizing immunological response following COVID-19 vaccination is an important public health issue. The objectives of the present analysis were to investigate the proportion, level and the determinants of humoral response from 21 days to three months after the first dose in vaccinated healthcare workers (HCWs). Methods: We abstracted data on level of anti-SARS-CoV-2 Spike antibodies (IgG) and sociodemographic characteristics of 17,257 HCWs from public hospitals and public health authorities from three centers in Northern Italy who underwent COVID-19 vaccination (average 70.6 days after first dose). We fitted center-specific multivariate regression models and combined them using random-effects meta-analyses. Results: A humoral response was elicited in 99.3% of vaccinated HCW. Female sex, young age, and previous COVID-19 infection were predictors of post-vaccination antibody level, and a positive association was also detected with pre-vaccination serology level and with time between pre- and post-vaccination testing, while a decline of antibody level was suggested with time since vaccination. Conclusions: These results stress the importance of analyzing retrospective data collected via occupational health surveillance of HCWs during the COVID-19 epidemic and following vaccination. They need to be confirmed in larger series based on prospectively collected data.

Abstract 917 | PDF Downloads 468

References

1. Li J, Concellón A, Yoshinaga K, Nelson Z, He Q, Swager TM. Janus Emulsion Biosensors for Anti-SARS-CoV-2 Spike Antibody. ACS Cent Sci. 2021;7:1166-75.
2. Thanh Le T, Andreadakis Z, Kumar A, Gómez Román R, Tollefsen S, Saville M, et al. The COVID-19 vaccine development landscape. Nat Rev Drug Discov. 2020;19:305-6.
3. Graham BS. Rapid COVID-19 vaccine development. Science. 2020;368:945-6.
4. Chen X, Chen Z, Azman AS, Sun R, Lu W, Zheng N, et al. Neutralizing antibodies against SARS-CoV-2 variants induced by natural infection or vaccination: a systematic review and pooled meta-analysis. Clin Infect Dis. 2021:ciab646.
5. Baker MG, Peckham TK, Seixas NS. Estimating the burden of United States workers exposed to infection or disease: A key factor in containing risk of COVID-19 infection. PLoS One 2020;15:e0232452
6. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72,314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020;323:1239-42.
7. Boffetta P, Violante F, Durando P, De Palma G, Pira E, Vimercati L, et al. Determinants of SARS-CoV-2 infection in Italian healthcare workers: a multicenter study. Sci Rep. 2021;11:5788.
8. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177–87.
9. Giefing-Kröll, C.; Berger, P.; Lepperdinger, G.; Grubeck-Loebenstein, B. How sex and age affect immune responses, susceptibility to infections, and response to vaccination. Aging Cell 2015;14:309-21.
10. Klein SL, Jedlicka A, Pekosz A. The Xs and Y of immune responses to viral vaccines. Lancet Infect. Dis. 2010;10:338–49.
11. Sariol CAA, Pantoja P, Serrano-Collazo C, Rosa-Arocho T, Armina-Rodríguez A, Cruz L, et al. Function Is More Reliable than Quantity to Follow Up the Humoral Response to the Receptor-Binding Domain of SARS-CoV-2-Spike Protein after Natural Infection or COVID-19 Vaccination. Viruses. 2021;13:1972.
12. Tubiana S, Burdet C, Houhou N, Thy M, Manchon P, Blanquart F, et al. High-risk exposure without personal protective equipment and infection with SARS-CoV-2 in-hospital workers - The CoV-CONTACT cohort. J Infect. 2021;82:186-230.